Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.
Stefan Michiels
No relevant relationships to disclose
Lina Pugliano
No relevant relationships to disclose
Delphine Grun
No relevant relationships to disclose
Jana Barinoff
No relevant relationships to disclose
David A. Cameron
No relevant relationships to disclose
Melody A. Cobleigh
Consultant or Advisory Role - Roche/Genentech
Angelo Di Leo
Consultant or Advisory Role - Roche
Honoraria - Roche
Stephen R. D. Johnston
Honoraria - GlaxoSmithKline; Roche
Research Funding - GlaxoSmithKline; Roche
Giampietro Gasparini
No relevant relationships to disclose
Bella Kaufman
No relevant relationships to disclose
Michel E. Marty
No relevant relationships to disclose
Valentina Nekljudova
No relevant relationships to disclose
Shani Paluch-Shimon
No relevant relationships to disclose
Frederique Penault-Llorca
Consultant or Advisory Role - Roche
Honoraria - GlaxoSmithKline; Roche
Dennis J. Slamon
No relevant relationships to disclose
Charles L. Vogel
No relevant relationships to disclose
Gunter Von Minckwitz
Honoraria - Roche
Research Funding - GlaxoSmithKline; Roche
Marc E. Buyse
Employment or Leadership Position - IDDI
Stock Ownership - IDDI
Martine J. Piccart-Gebhart
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech